BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Iruplinalkib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Iruplinalkib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05765877-2231@assetmemo.bio
DTSTAMP:20261121T004538Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Iruplinalkib: Phase 2 readout est. (NCT05765877)
DESCRIPTION:Iruplinalkib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Ce
 ll Lung Cancer\nEstimated primary completion: March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/iruplinalkib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05765877
URL:https://assetmemo.bio/drug/iruplinalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07870733-2231@assetmemo.bio
DTSTAMP:20261121T004538Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Iruplinalkib: Phase na readout est. (NCT07870733)
DESCRIPTION:Iruplinalkib\, phase na\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II 
 Single-arm Trial\nEstimated primary completion: 1 July 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iruplinalkib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07870733
URL:https://assetmemo.bio/drug/iruplinalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330076-2231@assetmemo.bio
DTSTAMP:20261121T004538Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Iruplinalkib: Phase 2 readout est. (NCT07330076)
DESCRIPTION:Iruplinalkib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ir
 uplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-posit
 ive NSCLC With High-risk Factors\nEstimated primary completion: 31 Decembe
 r 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/iruplinalkib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0733
 0076
URL:https://assetmemo.bio/drug/iruplinalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
